Stroke is a leading cause of serious and long-term disability and death worlwide, with
approximately 750,000 strokes occuring annually in the United States of America. The risk of …

The use of recombinant tissue plasminogen activator (rtPA) has been the standard of care
for treatment of acute ischemic stroke for several years. Studies evaluating the efficacy …

Background and Purpose: Early thrombolytic therapy with recombinant tissue-type
plasminogen activator is a theoretically attractive approach to the treatment of acute focal …

Early thrombolytic therapy with recombinant tissue-type plasminogen activator is a
theoretically attractive approach to the treatment of acute focal cerebral ischemia. In …

Background and Purpose—Acute ischemic stroke patients are infrequently treated with
recombinant tissue plasminogen activator (rtPA). We present unique population-based data …

Severe focal ischemia leads to neuronal death within minutes. Due to the cerebral collateral
network, in most instances occlusion of a major intracranial artery causes variable degrees …

ContextRecombinant tissue-type plasminogen activator (rt-PA) improves outcomes for
patients with acute ischemic stroke, but current approved use is limited to within 3 hours of …

Background and Purpose—The feasibility, safety, and efficacy of intravenous tissue
plasminogen activator (t-PA) for patients with acute ischemic stroke in clinical practice need …

Sixteen clinical centers in two countries have undertaken a prospective open angiography-
and computed tomography scan-based safety and efficacy dose-rate finding study of …

In 1995, the NINDS (National Institute of Neurological Disorders and Stroke) tPA (tissue
plasminogen activator) Stroke Study Group published the results of a large multicenter …